Cartesian Therapeutics, Inc. (RNAC) — SEC Filings
Cartesian Therapeutics, Inc. (RNAC) — 50 SEC filings. Latest: S-8 (Apr 30, 2026). Includes 24 8-K, 8 SC 13D/A, 7 10-Q.
View Cartesian Therapeutics, Inc. on SEC EDGAR
Overview
Cartesian Therapeutics, Inc. (RNAC) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-8 filed on Apr 30, 2026: Cartesian Therapeutics, Inc. filed an S-8 form on April 30, 2026, to register an unspecified number of securities to be offered under its employee benefit plans. This filing indicates the company is making shares available for its employees, likely as part of compensation or incentive programs. The
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 2 bearish, 48 neutral. The dominant filing sentiment for Cartesian Therapeutics, Inc. is neutral.
Filing Type Overview
Cartesian Therapeutics, Inc. (RNAC) has filed 1 S-8, 7 10-Q, 24 8-K, 1 DEFA14A, 1 10-K, 8 SC 13D/A, 2 S-1/A, 2 DEF 14A, 1 SC 13G, 1 S-1, 2 SC 13G/A with the SEC between Mar 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of RNAC's 45 recent filings, 2 were flagged as high-risk, 26 as medium-risk, and 17 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $1.850M |
| Net Income | -$37.726M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $143.384M |
| Operating Margin | N/A |
| Total Assets | $372.675M |
| Total Debt | $408.519M |
Key Executives
- Timothy A. Springer
- Michael K. Bradshaw, Jr.
- Murat Kalayoglu
- Elizabeth Hoge
- Seven One Eight Three Four Irrevocable Trust
- William R. Kolb
- Daniel S. Clevenger
- Carsten Brunn, Ph.D.
- Michael Singer
- Jonathan F. Miller
- CHAFEN LU
Industry Context
Cartesian Therapeutics operates in the highly competitive and capital-intensive clinical-stage biotechnology sector, focusing on cell therapy for autoimmune diseases. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Companies in this space often rely on strategic partnerships and substantial funding to advance their pipelines.
Top Tags
sec-filing (8) · 8-K (8) · financials (7) · schedule-13d (7) · amendment (6) · ownership-change (6) · 10-Q (5) · filing (4) · corporate-governance (4) · pharmaceutical (4)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Filing and Effectiveness Date | 2026-04-30 | Indicates when the securities registration became active. |
| iXBRL 10-Q Size | 1001035 | Size of the interactive data 10-Q document |
| Complete submission text file Size | 12680814 | Size of the complete submission text file |
| Net Loss (Q3 2025) | $35.902M | Increased from $24.183M in Q3 2024 |
| Net Loss (9 Months 2025) | $37.726M | Improved from $67.171M in 9 Months 2024 due to CVR adjustment |
| Total Revenue (9 Months 2025) | $1.850M | Decreased significantly from $39.672M in 9 Months 2024 |
| Research and Development Expenses (9 Months 2025) | $43.345M | Increased from $33.799M in 9 Months 2024 |
| Cash and Cash Equivalents (Sept 30, 2025) | $143.384M | Decreased from $212.610M at Dec 31, 2024 |
| Net Cash Used in Operating Activities (9 Months 2025) | $56.229M | Increased from $16.672M in 9 Months 2024 |
| Total Stockholders' Deficit (Sept 30, 2025) | $35.844M | Worsened from $6.802M at Dec 31, 2024 |
| Common Shares Outstanding (Oct 31, 2025) | 26,003,606 | Reflects recent share count |
| SEC File Number | 001-37798 | Identifies the company's filing history with the SEC. |
| IRS Employer Identification No. | 26-1622110 | Company's tax identification number. |
| Revenue | $0 | No revenue reported for Q2 2025 or the six months ended June 30, 2025, indicating pre-commercial stage. |
| Net Loss (Q2 2025) | $15.2M | Increased from $12.8 million in Q2 2024, reflecting higher operating expenses. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Cartesian Therapeutics, Inc. (RNAC)?
Cartesian Therapeutics, Inc. has 50 recent SEC filings from Mar 2024 to Apr 2026, including 24 8-K, 8 SC 13D/A, 7 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of RNAC filings?
Across 50 filings, the sentiment breakdown is: 2 bearish, 48 neutral. The dominant sentiment is neutral.
Where can I find Cartesian Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Cartesian Therapeutics, Inc. (RNAC) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Cartesian Therapeutics, Inc.?
Key financial highlights from Cartesian Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for RNAC?
The investment thesis for RNAC includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Cartesian Therapeutics, Inc.?
Key executives identified across Cartesian Therapeutics, Inc.'s filings include Timothy A. Springer, Michael K. Bradshaw, Jr., Murat Kalayoglu, Elizabeth Hoge, Seven One Eight Three Four Irrevocable Trust and 6 others.
What are the main risk factors for Cartesian Therapeutics, Inc. stock?
Of RNAC's 45 assessed filings, 2 were flagged high-risk, 26 medium-risk, and 17 low-risk.
What are recent predictions and forward guidance from Cartesian Therapeutics, Inc.?
Forward guidance and predictions for Cartesian Therapeutics, Inc. are extracted from SEC filings as they are enriched.